Incannex Healthcare (IXHL) Income from Continuing Operations (2022 - 2026)
Incannex Healthcare (IXHL) posted Income from Continuing Operations of 3883000.0 for Q1 2026, up 40.45% sequentially from 6521000.0 in Q4 2025, and up 2.14% YoY from 3801565.26 in Q1 2025.
Incannex Healthcare (IXHL) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Incannex Healthcare has reported Income from Continuing Operations for 5 years, with the latest figure at 3883000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 2.14% year-over-year to 3883000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 48414000.0 (down 122.97% YoY) and the FY2025 annual result came in at 46885000.0, down 154.0% from the prior year.
- Income from Continuing Operations advanced to 3883000.0 in Q1 2026 per IXHL's latest filing, from 6521000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 726000.0 in Q3 2023 and troughed at 31603000.0 in Q2 2025.
- A 5-year average of 6627714.29 and a median of 5330500.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations slumped 646.56% in 2024, then jumped 34.21% in 2025.
- Over 5 years, Income from Continuing Operations stood at 2918000.0 in 2022, then slumped by 79.61% to 5241000.0 in 2023, then decreased by 12.46% to 5894000.0 in 2024, then dropped by 10.64% to 6521000.0 in 2025, then surged by 40.45% to 3883000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 3883000.0, 6521000.0, and 6407000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Incannex Healthcare | 41.37 Mn | 41.37 Mn | - | -3.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.88 Mn |
| Dec 31, 2025 | -6.52 Mn |
| Sep 30, 2025 | -6.41 Mn |
| Jun 30, 2025 | -31.60 Mn |
| Mar 31, 2025 | -3.97 Mn |
| Dec 31, 2024 | -5.89 Mn |
| Sep 30, 2024 | -5.42 Mn |
| Jun 30, 2024 | -6.43 Mn |
| Mar 31, 2024 | -6.03 Mn |
| Dec 31, 2023 | -5.24 Mn |
| Sep 30, 2023 | -726,000.00 |
| Jun 30, 2023 | -4.17 Mn |
| Mar 31, 2023 | -3.57 Mn |
| Dec 31, 2022 | -2.92 Mn |